MERS-CoV Specific Neutra™ Antibody Products

Creative Biolabs provides a series of MERS-CoV antibody products and services to meet the various needs of researchers. Our offerings include:

• High-affinity antibodies for specific detection of MERS-CoV.
• Custom antibody development services tailored to your unique research requirements.
• Antibody characterization and validation services to ensure data reliability.
• Assay development support for MERS-CoV research.

Our solutions deliver the tools and expertise necessary to overcome the obstacles in MERS-CoV research.

Contact our team to get an inquiry now!

Introduction of MERS-CoV

Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a non-segmented RNA betacoronavirus within the Merbecovirus clade, drives zoonotic transmission through dromedary camel reservoirs, posing persistent epidemic threats. Its 30.1-kb single-stranded genome specifies four structural modules:

1. Homotrimeric S glycoprotein enabling dipeptidyl peptidase 4 (DPP4)-mediated invasion via clathrin-dependent uptake or direct membrane merger;
2. E protein, an ionophoric viroporin directing viral morphogenesis through oligomeric pore formation;
3. M protein, a triple-pass transmembrane organizer templating virion assembly at ERGIC membranes;
4. N protein, stabilizing the ribonucleocapsid via arginine-serine motif-mediated RNA compaction.

Fig. 1 Schematic structures of MERS-CoV S protein.¹

Pathogenic Mechanism of MERS-CoV

Post-entry, the 5′ cap-dependent translation of ORF1a/1ab yields polyproptides processed by papain-like (PLpro) and 3C-like (3CLpro) proteases into replication-transcription complexes (RTCs). These RTCs co-opt host rough ER membranes for discontinuous RNA synthesis, generating negative-sense intermediates that template new genomes. Virion morphogenesis exploits ESCRT machinery for M protein-directed membrane scission, yielding progeny virions with distinctive 120–160 nm pleomorphism.

Pathogenetically, MERS-CoV subverts innate immunity via MDA5/MAVS pathway antagonism (NS4b-mediated) and NLRP3 inflammasome hyperactivation, driving IL-1β/IL-18 overproduction. This immunopathology manifests as a cytokine triad, precipitating alveolar-capillary leakage and hyaline membrane formation in ARDS. Extrapulmonary dissemination—notably renal tubular tropism via basolateral DPP4 targeting—induces acute cortical necrosis, distinguishing it from other betacoronaviruses.

Antibody against Influenza B Virus

Recombinant monoclonal antibodies (mAbs) demonstrating high virus-neutralizing efficacy constitute a primary biotherapeutic intervention against coronaviruses, including MERS-CoV. These biologics selectively target the homotrimeric spike (S) protein—a class I fusion apparatus proteolytically processed into receptor-binding (S1) and fusogenic (S2) domains. MERS-CoV cellular entry commences with S1 binding to dipeptidyl peptidase 4 (CD26/DPP4) receptors, followed by S2-mediated membrane integration via HR1-HR2 helical fusion core assembly. Structural elucidation of the S1 receptor-binding domain (RBD)-CD26 complex (cryo-EM: 3.8 Å resolution) revealed the RBD's bipartite architecture—a conserved core subdomain and a receptor-interacting outer subdomain bearing critical β5-β6 loop residues. Rational mAb design exploiting these structural blueprints demonstrates that steric hindrance of the RBD-CD26 ligand-receptor interface (e.g., mAb G2) achieves viral neutralization. Preclinical validation in transgenic hDPP4 murine models confirms that RBD-targeted polyclonal sera reduce pulmonary viral titers by ≥3 log10, substantiating epitope-focused vaccine strategies.

Why Choose Us?

Creative Biolabs offers unparalleled expertise and cutting-edge technology. We are dedicated to accelerating your MERS-CoV research. We provide:

• Expertise: Our team comprises leading scientists with extensive experience in MERS-CoV research, animal model development, and antibody engineering.
• Cutting-Edge Technology: We utilize the latest technologies, including advanced recombinant DNA technology, high-throughput screening platforms, and innovative protein engineering techniques.
• Customized Solutions: Our customization services are able to suit your specific research needs, ensuring that you receive the most relevant and effective solutions.
• High-Quality Products and Services: Adhere to rigorous quality control standard, we are able to ensure the accuracy, reliability, and reproducibility of our results.
• Accelerated Research: Our tools and expertise can significantly accelerate your research timeline, enabling you to achieve your goals faster and more efficiently.

For more information about Creative Biolabs' MERS-CoV antibodies and services, please contact us.

REFERENCE

1. Zhou, Yusen, et al. "Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain." Viruses 11.1 (2019): 60. Distributed under Open Access license CC BY 4.0, without modification.